Author

W. Porter

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Assay:proteomics· 1

Frequent Co-Authors

B. Lim· 1 shared C. Young· 1 shared E. B. Goff· 1 shared G. L. Wyatt· 1 shared G. V. Echeverria· 1 shared J. Lee· 1 shared J. P. Barrish· 1 shared K. E. Pendleton· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

B. Lim

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy treatment

M. L. Baek, J. Lee, K. E. Pendleton, M. J. Berner, E. B. Goff, L. Tan, S. A. Martinez, T. Wang, M. D. Meyer, B. Lim, J. P. Barrish, W. Porter, P. L. Lorenzi, G. V. Echeverria

This study identifies how residual triple negative breast cancer cells adapt mitochondrial structure and function to survive chemotherapy, showing that DNA-damaging agents promote mitochondrial fusion and OXPHOS, which can be targeted with OPA1 inhibitors.

bioRxiv · Feb 25, 2022Cancer Biology

Cross-talk between SIM2s and NFkB regulates cyclooxygenase 2 expression in breast cancer

G. L. Wyatt, C. Young, L. Crump, V. Wessells, T. Gustafson, Y.-Y. Fan, R. Chapkin, W. Porter, T. R. Lyons

This study shows that SIM2s inhibits NFkB activation and COX-2 expression in breast cancer, suggesting a potential therapeutic target.

bioRxiv · May 10, 2019Cancer Biology